Australia-based Mesoblast Ltd (NASDAQ: MESO; ASX: MSB) acquired an exclusive worldwide license to a patented chimeric antigen receptor technology platform developed at Mayo Clinic, obtained through the acquisition of an unnamed startup formed to commercialize the intellectual property. The transaction is intended to extend Mesoblast's allogeneic cellular medicine strategy by layering targeted CAR constructs onto its existing mesenchymal stromal cell platforms to increase tissue-homing precision and immunomodulatory potency.

The consideration consisted entirely of Mesoblast ASX ordinary shares; no cash component, milestone payments, or total deal value were disclosed. As part of the agreement, Mayo Clinic will provide in-kind support toward further technology development, including GMP manufacturing activities. Mayo retains a financial interest in the technology through the license arrangement and will direct any revenue received toward its not-for-profit mission. No transaction closing conditions or expected closing date were disclosed, as the acquisition was announced as complete.

CAR-MSC engineering and mechanism

The foundational science originates from work by Mayo Clinic investigators published in Nature Biomedical Engineering (Sirpilla et al., 2024), which identified CAR-MSC constructs with enhanced tissue-specific targeting capacity in inflammatory and autoimmune disease contexts. Conventional MSC therapies rely on the cells' inherent homing capabilities and paracrine immunomodulatory properties — releasing anti-inflammatory factors that modulate multiple effector arms of the immune system. The limitation of unmodified MSCs is that homing efficiency to specific inflamed tissue sites is variable, constraining potency at the target site.

The CAR constructs Mesoblast licenses address this by genetically engineering surface receptors onto MSCs that direct them with greater specificity toward inflamed tissue. This approach applies the targeting logic of CAR-T cell engineering — where a synthetic receptor redirects a lymphocyte toward a defined antigen — to a stromal cell chassis optimized for immunosuppression and tissue repair rather than cytotoxicity. The result is a CAR-MSC with retained immunomodulatory function and substantially enhanced homing to the intended inflammatory microenvironment.

Two near-term applications are identified in the press release. The first applies CAR-MSCs engineered for enhanced targeting to inflamed bowel, addressing ulcerative colitis and Crohn's disease, indications where Mesoblast's existing remestemcel-L platform is already in development for biologic-resistant inflammatory bowel disease. The second involves CAR-MSCs engineered to express CD19 on their surface, enabling targeted interaction with B cells to induce remission in Lupus Nephritis and other B cell-mediated autoimmune diseases where durable immunomodulation without the toxicity profile of cytotoxic approaches remains an unmet need.

Strategic fit with Mesoblast platform

Mesoblast's commercial and clinical foundation rests on two allogeneic stromal cell platforms: remestemcel-L and rexlemestrocel-L. Ryoncil (remestemcel-L-rknd) holds FDA approval for steroid-refractory acute graft-versus-host disease in pediatric patients aged two months and older — the first FDA-approved MSC therapy — and is in development for SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is in development for heart failure and chronic low back pain.

The CAR platform acquisition applies a precision engineering layer to products already in development. The acquisition positions Mesoblast to develop a new generation of MSC products in which tissue-specific targeting is a designed, controllable parameter rather than a function of baseline cell biology alone.

---

Spot something wrong? Report an issue with this article